Farxiga (dapagliflozin) / Ono Pharmaceutical, AstraZeneca - LARVOL DELTA

In silico assessment of benzyl C-analogues of dapagliflozin as potential SGLT2 inhibitors for type 2 diabetes. (PubMed, J Mol Graph Model) - "Crucially, the computational ranking strongly correlated with available in vitro data, where A1 exhibited the highest inhibitory potency (IC50=0.64nM). These combined findings suggest that compound A1 is a promising candidate, which warrants further experimental validation for T2D treatment."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

IECA-MEX: Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease (clinicaltrials.gov) - P4 | N=200 | Not yet recruiting | Sponsor: Centenario Hospital Miguel Hidalgo

New P4 trial • Chronic Kidney Disease • Nephrology • Renal Disease

A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food (clinicaltrials.gov) - P1 | N=26 | Not yet recruiting | Sponsor: AstraZeneca

New P1 trial

SFRNDM2: Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes (clinicaltrials.gov) - P4 | N=4 | Terminated | Sponsor: Boston University | N=50 ➔ 4 | Recruiting ➔ Terminated; The study was halted early because of the inability to enroll participants.

Enrollment change • Trial termination • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

The Effect of Dapagliflozin on Myocardial Strain in Patients With Acute Heart Failure (clinicaltrials.gov) - P=N/A | N=188 | Not yet recruiting | Sponsor: Qilu Hospital of Shandong University

New trial • Cardiovascular • Congestive Heart Failure • Heart Failure

Dapagliflozin Modulates Brain–Kidney Inflammatory Crosstalk in Chronic Kidney Disease–Associated Ischemic Stroke (ISC 2026) - "Post-stroke treatment partially attenuated these pathological responses and this suggests time-dependent efficacy.Overall, these findings highlight that dapagliflozin confers dual neuroprotective and renoprotective effects by modulating the brain–kidney inflammatory axis. This supports its translational potential for improving stroke outcomes in patients with CKD."

Late-breaking abstract • Cardiovascular • Chronic Kidney Disease • Fibrosis • Ischemic stroke • Nephrology • Renal Disease

A Randomized Controlled Clinical Study of Mulberry Twig Alkaloids Tablets versus Dapagliflozin in Patients with Type 2 Diabetes: Efficacy and Safety Evaluation (ChiCTR) - P4 | N=224 | Not yet recruiting | Sponsor: NanJing First Hospital; NanJing First Hospital

New P4 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

BASELINE KIDNEY FUNCTION AND SAFETY AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS HOSPITALIZED WITH HEART FAILURE (ACC 2026) - "Abstract is embargoed at this time."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure

A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin (clinicaltrials.gov) - P3 | N=118 | Not yet recruiting | Sponsor: Hanmi Pharmaceutical Company Limited

New P3 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Risk of prostatitis in patients with type 2 diabetes mellitus: An observational retrospective cohort study of canagliflozin versus other antihyperglycemic agents using propensity score matching. (PubMed, PLoS One) - "This analysis found no evidence of a statistically significantly increased risk of prostatitis among adult male patients with T2DM receiving canagliflozin compared with the other AHAs evaluated in this study."

Journal • Observational data • Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Evaluation of dose-dependent effects of dapagliflozin on urinary glucose and plasma ketone bodies in healthy dogs. (PubMed, Am J Vet Res) - "In healthy dogs, a single oral administration of dapagliflozin at 1.0 mg/kg induced both ketogenic and diuretic effects. This study provides preliminary insight into dapagliflozin's effects in healthy dogs; further studies are needed to assess relevance in dogs with heart failure."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease (clinicaltrials.gov) - P4 | N=731 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed • Chronic Kidney Disease • Nephrology • Renal Disease

NOT ONE-SIZE-FITS-ALL: RACIAL/ETHNIC VARIATION IN EMPAGLIFLOZIN VS DAPAGLIFLOZIN OUTCOMES (ACC 2026) - "Abstract is embargoed at this time."

Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

Case Report: Euglycemic ketoacidosis in a non-diabetic patient: a rare adverse effect of SGLT2 inhibitor therapy. (PubMed, Front Endocrinol (Lausanne)) - "We report a 58-year-old man with ischemic cardiomyopathy (LVEF 35%) and stage 2 chronic kidney disease who developed nausea, vomiting, and fatigue two weeks after initiating dapagliflozin...This case highlights that SGLT2 inhibitors can precipitate euglycemic ketoacidosis even in non-diabetic patients. Because normal glucose levels may obscure recognition, clinicians should maintain a high index of suspicion and perform ketone testing in patients on SGLT2 therapy who present with unexplained gastrointestinal or constitutional symptoms."

Adverse events • Journal • Cardiomyopathy • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Fatigue • Heart Failure • Hepatology • Infectious Disease • Liver Failure • Metabolic Disorders • Nephrology • Renal Disease

Management of lenvatinib-induced proteinuria with dapagliflozin. (PubMed, Medicina (B Aires)) - "Dapagliflozin is a sodiumglucose co-transporter type 2 (SGLT2) inhibitor that acts in the proximal convoluted tubule, improving renal function in diabetic and non-diabetic patients. SGLT2 inhibitors may have a role in the management of lenvatinib-induced proteinuria, however further study is needed."

Journal • Cardiovascular • Hypertension • Metabolic Disorders • Oncology • Pulmonary Arterial Hypertension • Renal Disease • Solid Tumor • Thyroid Gland Carcinoma

A Hierarchical Composite Endpoint for Chronic Kidney Disease Progression in Patients with Focal Segmental Glomerulosclerosis. (PubMed, Clin J Am Soc Nephrol) - "Our findings suggest that a CKD progression HCE, which integrates established CKD endpoints and eGFR slope, provides a sensitive and efficient measure to assess treatment effects in patients with FSGS. Validation of the HCE in prospective clinical trials will support its implementation."

Clinical • Journal • Cardiovascular • Chronic Kidney Disease • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Nephrology • Renal Disease

Change in dapagliflozin trial eligibility status and prognosis among patients with acute heart failure with preserved ejection fraction. (PubMed, J Chin Med Assoc) - "Although most patients with decompensated HFpEF met the DELIVER criteria, 41.7% of initially ineligible patients became eligible after 1 year. However, no differences were observed in the adjusted 1-year rate of all-cause mortality or cardiovascular mortality and HHFs."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Renoprotective effects of dapagliflozin in diabetic patients with chronic kidney disease: A retrospective observational study. (PubMed, Br J Clin Pharmacol) - "The use of dapagliflozin was associated with significant renal protection and lower hospitalizations without compromising patient safety. These findings support the beneficial role of dapagliflozin in preserving renal function in this high-risk population."

Journal • Observational data • Retrospective data • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

The effect of SGLT2 inhibitors on left atrial Function in patients with Hypertension: A prospective, Randomized, open-access, blinded endpoint assessment study (PROBE-RCT) (ChiCTR) - P=N/A | N=148 | Not yet recruiting | Sponsor: The Second Hospital of Tianjin Medical University; The Second Hospital of Tianjin Medical University

New trial • Cardiovascular • Hypertension

CARDIOVASCULAR EFFECTS OF DAPAGLIFLOZIN IN PATIENTS ON CHRONIC DIALYSIS: THE DARE-ESKD-2 RANDOMIZED CLINICAL TRIAL. (ACC 2026) - "Abstract is embargoed at this time."

Clinical • Cardiovascular

SGLT2 INHIBITOR DAPAGLIFLOZIN ATTENUATES CARDIOMYOCYTE INJURY INDUCED BY PI3Kα-SELECTIVE INHIBITOR ALPELISIB AND FULVESTRANT UNDER HYPERGLYCEMIA (ACC 2026) - "Abstract is embargoed at this time."

Diabetes • PIK3CA

SGLT2-NS: SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome (clinicaltrials.gov) - P2/3 | N=75 | Active, not recruiting | Sponsor: Mansoura University | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Glomerulonephritis • Nephrology • Renal Disease

Preliminary Clinical Study on the Effect of Dapagliflozin on the Efficacy in Patients With Refractory Non-infectious Uveitis (ChiCTR) - P4 | N=20 | Not yet recruiting | Sponsor: The Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; The Ninth People's Hospital Affiliated to Shanghai Jiao To

New P4 trial • Ocular Inflammation • Ophthalmology • Uveitis

Pharmacovigilance analysis of the association between SGLT-2 inhibitors and diabetic foot infections using the FAERS database: An observational study. (PubMed, Diabetes Res Clin Pract) - "A strong, agent-specific signal links canagliflozin to DFI. Clinicians should prioritise foot surveillance and consider safer SGLT-2 inhibitor alternatives in high-risk patients."

Adverse events • Journal • Observational data • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Infectious Disease • Metabolic Disorders • Type 2 Diabetes Mellitus

Dapagliflozin attenuates hypothyroidism induced liver and lung dysfunction via regulation of mitophagy and apoptosis. (PubMed, Mol Biol Rep) - "Dapagliflozin (DAPA) is an anti diabetic drug posses antioxidant and anti apoptotic properties AIM OF THE STUDY: The aim of this work is to identify the effect of DAPA on disturbance of liver and lung functions result from hypothyroidism MATERIALS AND Twenty four rats (6 rats/group) were divided into four groups: control group, DAPA group that received DAPA (1 mg/kg/day for five weeks), PTU group that received propylthiouracil (15 mg/kg/day for five weeks), PTU+ DAPA group that received PTU and DAPA as described in the other groups Hypothyroidism induced oxidative stress associated mitophagy disturbance in both lung and liver with development of apoptosis in liver. DAPA avoided this effect DAPA protects against liver and lung injury result from hypothyroidism."

Journal • Endocrine Disorders • Liver Failure • Pulmonary Disease • Respiratory Diseases